Paul Hastings LLP advised Semnur Pharmaceuticals, Inc., a wholly owned subsidiary of Scilex Holding Company (Nasdaq: SCLX) and Denali Capital Acquisition Corp. (Nasdaq: DECA), in the signing of an agreement and plan of merger for a proposed business combination, for a pre-transaction equity value of Semnur of $2.5 billion.

Semnur is a clinical-late-stage specialty pharmaceutical company focused on the development and commercialization of novel non-opioid pain therapies. The combination would create a publicly traded biopharma company and further provide investment into Semnur.

Chair of the Corporate Practice in Palo Alto Jeff Hartlin and partner Elizabeth Razzano led the Paul Hastings team, which included associates Mark Cramer, Youssef Aziz, Rose Lu, Erik Oakley, and Daniel Jun.

More details about the transaction can be found here.

About Paul Hastings

With widely recognized elite teams in finance, mergers & acquisitions, private equity, restructuring and special situations, litigation, employment and real estate, Paul Hastings is a premier law firm providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers and corporations.